Antiphospholipid syndrome and connective tissue overlap

• Antiphospholipid syndrome (APS) is an autoimmune thrombophilia: a person has persistently positive antiphospholipid antibodies (aPL) together with a venous or arterial thrombosis, or with specific pregnancy complications.
• The antibodies are lupus anticoagulant, anticardiolipin and anti-beta-2-glycoprotein I. Because infection can produce transient antibodies, laboratory positivity has to be confirmed on a second occasion at least 12 weeks later before anyone is labelled as having APS. ^{[1] [2] [10]}
• Risk is not the same for everyone. A "high-risk aPL profile" means lupus anticoagulant positivity, double or triple antibody positivity, or persistently high titres; a "low-risk profile" is a single low-to-moderate titre antibody. ^[1]
• Treatment follows the risk and the event: primary thromboprophylaxis with low-dose aspirin for high-risk aPL carriers; long-term vitamin K antagonist with INR 2-3 after a first venous thrombosis; a vitamin K antagonist (INR 2-3 or 3-4) after a first arterial thrombosis; and combination low-dose aspirin plus prophylactic heparin in pregnancy after obstetric APS. ^[1]
• Rivaroxaban is not suitable for patients with triple aPL positivity, especially with arterial events, because thrombosis recurrences were higher than with warfarin in the randomised trial available. ^{[1] [2]}
• Mixed connective tissue disease (MCTD) and undifferentiated connective tissue disease (UCTD) are the two other overlap conditions in this topic: MCTD is an overlap syndrome defined by anti-U1 RNP antibodies and features of lupus, scleroderma and myositis, while UCTD is autoimmunity that has not yet met the criteria for any named disease. ^{[7] [8] [9]}

By the end of this page you should be able to:

1. Explain what antiphospholipid antibodies are, how they produce thrombosis and pregnancy loss, and what separates a high-risk from a low-risk aPL profile.
2. Apply the Sydney classification criteria and the 2023 ACR/EULAR classification criteria to decide whether a patient has APS. ^[10]
3. Plan the investigation and interpretation of aPL testing, including the 12-week confirmation rule and the effect of acute illness or treatment.
4. Choose and monitor anticoagulation for venous and arterial APS, for recurrent events, and for pregnancy.
5. Recognise mixed connective tissue disease, state the role of anti-U1 RNP, and list its diagnostic and organ-based complications.
6. Define undifferentiated connective tissue disease, give its preliminary criteria, and describe its long-term evolution and damage.

APS is both a rheumatic and a vascular disease. Thrombosis can occur in any arterial or venous territory, at any age, and in a patient who looks otherwise healthy. Some aPL carriers never develop APS at all; the antibodies are a risk factor, not a diagnosis by themselves. Catastrophic APS (CAPS) is the rare acute form in which small-vessel thrombosis hits several organs within days.

APS is uncommon. Well-designed, multi-ethnic population studies are still limited, so precise prevalence figures remain uncertain. What we can say with reasonable confidence comes from large cohorts. ^[4]

• About 91% of people with APS are alive at 10 years. ^[4]
• Catastrophic APS develops in about 1% of affected people and is fatal in about half of cases. ^[4]
• Venous thrombosis is the most common macrovascular presentation: deep vein thrombosis and pulmonary embolism. Stroke and transient ischaemic attack are the most common arterial events, followed by myocardial infarction. ^{[4] [5]}
• Microvascular disease is real but less obvious: livedoid vasculopathy, skin ulcers, and APS nephropathy with renal microthrombi, often needing a biopsy for confirmation. ^[4]
• In SLE, aPL are commonly tested; only a subset develop APS, which is one reason to test SLE patients at least once. ^[1]

The cause is autoimmune. Autoantibodies bind to phospholipid-binding proteins, especially beta-2-glycoprotein I and prothrombin, and the result is thrombosis and placental injury rather than bleeding. APL can be induced by infections, drugs and, rarely, malignancy; these are usually low-titre and transient and do not create APS unless they persist. ^{[5] [6]}

Risk of a clinical event rises with:

• A high-risk aPL profile: lupus anticoagulant, double or triple antibody positivity, or persistently high titres. ^[1]
• Coexisting systemic autoimmune disease, especially SLE. ^[1]
• Traditional vascular risk factors: smoking, hypertension, dyslipidaemia, diabetes, obesity, immobility and the postpartum period. ^[1]
• Pregnancy itself, which is a physiologically thrombophilic state.
• A prior thrombotic or obstetric APS event, which markedly raises the chance of a further event. ^[1]

Low-risk profiles (a single, low-to-moderate titre anticardiolipin or anti-beta-2-glycoprotein I antibody, especially if transient) are far less predictive and are the commonest reason for an apparent "positive APS test" that does not lead to treatment. ^[1]

Antiphospholipid antibodies produce both thrombosis and inflammation, and each of the clinical features can be reasoned backwards from that.

1. Antibody formation. B cells produce aPL directed against phospholipid-binding proteins, mainly beta-2-glycoprotein I. The standard laboratory tests detect IgG or IgM antibodies (IgA forms are not in the classification criteria but are used in some settings). ^{[1] [6]}
2. Endothelial and platelet activation. Antibody-antigen complexes activate endothelium, monocytes and platelets, promoting tissue factor expression and adhesion molecules.
3. Interference with natural anticoagulants. APL inhibit the protein C and S pathway and displace annexin A5 from phospholipid surfaces, removing a normal brake on clotting.
4. Complement and neutrophils. In obstetric APS, complement activation and neutrophil extracellular traps amplify placental inflammation and thrombosis.
5. Clinical result. Venous thrombosis (most often deep vein thrombosis that may embolise to the lungs), arterial thrombosis (stroke, transient ischaemic attack, myocardial infarction), and placental failure (miscarriage, fetal death, pre-eclampsia, fetal growth restriction). Non-thrombotic effects include livedo, thrombocytopenia and valve lesions.

The key clinical consequence is that inflammation and thrombosis occur together, which is why APS also mimics and overlaps with lupus and other connective tissue diseases, and why antiphospholipid antibodies are tested in many of those conditions.

Thrombosis is the defining problem of thrombotic APS.

• Deep vein thrombosis with or without pulmonary embolism: the commonest venous presentation. ^[4]
• Ischaemic stroke or transient ischaemic attack: the commonest arterial presentation, and important because it can occur in young people. ^[4]
• Myocardial infarction, mesenteric or renal artery thrombosis, retinal artery occlusion, and peripheral arterial occlusion. ^[4]
• Events recur. They often recur in the same vascular bed: venous events follow venous events, arterial follow arterial. ^[1]
• Thrombosis may be the first (and only) clue to an otherwise silent autoimmune disease.

Obstetric APS is the other defining presentation. Criteria-level morbidity is:

• Three or more consecutive spontaneous miscarriages before the 10th week of gestation;
• One or more fetal deaths at or beyond the 10th week;
• One or more premature births before the 34th week due to eclampsia, severe pre-eclampsia, or recognised placental insufficiency. ^[10]

In practice the picture is broader: recurrent early losses, a single mid-trimester loss, placental abruption, early-onset severe pre-eclampsia, fetal growth restriction and placental insufficiency on ultrasound. These are managed as obstetric APS even when they are "non-criteria" because the antibody confers a real risk. ^[1]

• Livedo racemosa or reticularis and skin ulceration.
• Thrombocytopenia, often mild, and autoimmune haemolytic anaemia (especially in secondary APS).
• Cardiac valve thickening or small vegetations (Libman-Sacks), which are non-infective and do not respond to antibiotics.
• APS nephropathy with hypertension and renal dysfunction.
• Cognitive or visual changes from cerebral microvascular disease.

These features explain why APS overlaps clinically with SLE, and why an SLE patient with livedo and thrombocytopenia should be assessed for aPL.

This is the fulminant end of the spectrum: thrombotic microangiopathy in multiple vascular beds over days, with fever and confusion. Triggers include stopping anticoagulation, infection, surgery, trauma and pregnancy. Earlier recognition and combined heparin, glucocorticoids and plasma exchange or intravenous immunoglobulin (IVIG) have improved survival, but mortality remains high. ^{[1] [4]}

The difficult distinction is between APS and other causes of thrombosis, pregnancy loss and inflammatory symptoms.

The wrong test and the wrong timing are the commonest errors. APL assays are technical and must be interpreted in context.

Three assays are used, and they should be ordered together to build a risk profile. ^[6]

• Lupus anticoagulant (LA): a functional coagulation test. A prolonged phospholipid-dependent clotting time that does not correct on mixing and is corrected by added phospholipid. Because no single assay catches every antibody, at least two different LA confirmatory tests should be performed. ^{[1] [6]}
• Anticardiolipin (aCL) antibodies: IgG or IgM, measured by enzyme-linked immunosorbent assay (ELISA). Medium-high titre is greater than 40 phospholipid units (GPL or MPL) or greater than the 99th percentile. ^[1]
• Anti-beta-2-glycoprotein I antibodies: IgG or IgM, also by standardised ELISA; medium-high titre is greater than the 99th percentile. ^[1]

Persistent positivity means the same test (or at least one of the family) is positive on two occasions at least 12 weeks apart. Single positive results during acute illness, infection, thrombosis, treatment with anticoagulant or contraception, and postpartum do not count. ^{[1] [10]}

LA is the antibody most closely linked to thrombosis. Anticardiolipin antibodies are more sensitive but less specific for predicting thrombosis. Anti-β2GPI antibodies complete the triple (all 3 positive) profile with the highest risk. ^{[6] [1]}

• Full blood count and film: thrombocytopenia or haemolysis.
• Baseline urea, creatinine and urinalysis for renal involvement; consider a renal biopsy when nephropathy is suspected.
• Echocardiography when cardiac valve lesions or pulmonary hypertension are suspected.
• Renal, cerebral or pulmonary imaging as dictated by the presentation.
• In pregnancy: placental ultrasound, uterine artery Doppler in high-risk units, and monitoring for pre-eclampsia and fetal growth restriction.

• Warfarin prolongs the LA test and can make interpretation impossible; test before starting, or stop warfarin and bridge with heparin.
• Direct oral anticoagulants also interfere with LA assays.
• Acute thrombosis, infection and inflammation can transiently produce aPL; never diagnose from one sample.
• Unnecessary testing (for example in routine screening of healthy people or isolated prolonged partial thromboplastin time with no clinical context) causes false positives and overtreatment.

Classification criteria are research standards, not a diagnosis, but in practice clinicians use them to decide treatment. Two are important.

The Sydney revision of the Sapporo criteria remains the most widely used standard. ^[10]

• At least one clinical criterion plus one laboratory criterion.
• Clinical: vascular thrombosis (any site, once, in objectively confirmed venous, arterial or small-vessel disease); or pregnancy morbidity of three specific types.
• Laboratory: lupus anticoagulant, medium-high titre anticardiolipin IgG/IgM, or medium-high titre anti-beta-2-glycoprotein I IgG/IgM.
• Laboratory positivity confirmed on two occasions at least 12 weeks apart.
• Medium-high titre aCL means greater than 40 phospholipid units (GPL or MPL) or greater than the 99th percentile; anti-beta-2-glycoprotein I greater than the 99th percentile. ^[1]

This gives a dichotomous yes or no diagnosis but does not distinguish risk levels, which is the main weakness in studies.

The 2023 ACR/EULAR criteria are a weighted, hierarchical system designed for studies and trials, with higher specificity. ^[3]

• Entry criterion: at least one positive aPL test within three years of identifying an aPL-associated clinical criterion. ^[3]
• Additive weighted criteria in six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, haematological) and two laboratory domains (lupus anticoagulant; solid-phase IgG/IgM anticardiolipin and/or anti-beta-2-glycoprotein I).
• A score of at least three points in the clinical domain and at least three points in the laboratory domain classifies the patient as having APS.
• Against the 2006 criteria in validation, specificity was 99% versus 86%, but sensitivity fell to 84% versus 99%. ^[3]

In clinic, this means some patients treated as having APS under the Sydney system (for example with a single antibody and a clinical feature) will not meet the 2023 criteria. Both systems demand persistence and appropriate titre, and neither replaces clinical judgment.

This distinction, rather than the criteria label, drives most treatment decisions.

The aim is to prevent thrombosis and pregnancy complications while avoiding bleeding. Risk stratification (aPL profile, SLE, traditional risk factors), counselling about adherence and INR monitoring, and strict control of cardiovascular risk factors come first. ^[1]

Key general measures:

• Explain the diagnosis, the need for long-term anticoagulation when thrombosis has occurred, the target INR, and drug and food interactions.
• Screen for and control hypertension, dyslipidaemia, diabetes and smoking; encourage activity and diet.
• Use low molecular weight heparin (LMWH) prophylaxis in high-risk situations: surgery, hospitalisation, immobilisation and the puerperium.
• Plan pregnancy before it happens; warfarin is teratogenic.

• Asymptomatic carriers with a high-risk aPL profile, with or without traditional risk factors: low-dose aspirin (LDA) 75-100 mg daily is recommended. ^[1]
• Patients with SLE and no history of thrombosis or pregnancy complications:
  • High-risk aPL profile: LDA recommended.
  • Low-risk aPL profile: LDA may be considered. ^[1]
• Hydroxychloroquine, used for SLE, also has an antithrombotic effect and is continued; LDA adds benefit rather than replaces it. ^[1]
• Non-pregnant women with a history of obstetric APS only: LDA after risk-benefit evaluation. ^[1]

LDA is cheap, reasonably safe, and supported by meta-analysis data showing roughly half the risk of first thrombosis in high-risk aPL carriers. ^[2]

• Initial treatment is heparin (LMWH preferred, or unfractionated heparin if needed), then warfarin with a target INR of 2-3. ^[1]
• For unprovoked venous thrombosis, anticoagulation is continued long term. ^[1]
• For provoked venous thrombosis, the duration follows standard international guidance for provoked thrombosis, with longer anticoagulation considered when the aPL profile is persistently high-risk or other risk factors remain. ^[1]
• A target INR above 3 has not been shown to reduce recurrences compared with 2-3 in venous thrombosis, and may increase bleeding; it is not recommended routinely. ^{[1] [2]}
• Rivaroxaban should not be used in patients with triple aPL positivity because a randomised trial was stopped early after excess thrombotic events, mainly arterial, in the rivaroxaban arm. Direct oral anticoagulants (DOACs) may be considered for people who cannot achieve a target INR despite good adherence, or who are intolerant of warfarin (for example allergy), but should not be first choice. ^{[1] [2]}

• Warfarin is recommended over low-dose aspirin alone. ^[1]
• Target INR 2-3 or 3-4 is acceptable, weighing the individual's risk of recurrent thrombosis against bleeding; or INR 2-3 plus low-dose aspirin. ^[1]
  • One randomised trial stratified for arterial thrombosis found no significant difference between INR 3-4 and 2-3, but the sample was small and the high-intensity target was rarely achieved. ^[2]
  • Some centres prefer INR 3-4 after stroke because of the higher recurrence risk in arterial APS.
• DOACs are not recommended for definite APS with arterial events because of the high risk of recurrence, particularly with triple positivity. ^[1]

This is the one place where guidelines genuinely differ in emphasis rather than in a single correct number: the choice between INR 2-3 and 3-4 after an arterial event is made case by case, after discussing risks and preferences. ^[1]

• Check adherence, the intensity of anticoagulation, and for other thrombosis risk factors (cancer, immobility, other thrombophilias) before escalating.
• If the target INR of 2-3 has been achieved, consider adding LDA, raising the target to 3-4, or switching to LMWH. ^[1]
• Recurrent venous events despite adequate INR may also be treated with LMWH because of concerns about "warfarin failure" in some cases.
• Recurrent arterial events: increase INR target to 3-4, add LDA, or switch to LMWH; consider antimalarials and statins as adjuncts. ^[1]

Pregnancy is both a reason to treat and a reason to change drugs.

• High-risk aPL profile, no prior thrombosis or pregnancy complications (with or without SLE): consider LDA 75-100 mg daily during pregnancy. ^[1]
• Obstetric APS only (no prior thrombosis):
  • Three or more first-trimester losses, or any fetal death at or beyond the 10th week: LDA plus prophylactic-dose heparin (LMWH preferred for practical reasons) throughout pregnancy. ^[1]
  • Delivery before the 34th week due to eclampsia, severe pre-eclampsia or placental insufficiency: LDA alone or combined with prophylactic heparin, tailored to the individual's risk profile. ^[1]
  • "Non-criteria" events (two first-trimester losses, or delivery at or after 34 weeks due to severe pre-eclampsia/eclampsia): LDA alone or with heparin, based on an individual risk profile (aPL profile, SLE, previous live births, additional risk factors). ^[1]
• Recurrent pregnancy complications despite LDA plus prophylactic heparin: increasing the heparin dose to therapeutic, adding hydroxychloroquine, or adding low-dose prednisolone in the first trimester may be considered. IVIG may be considered in highly selected cases. ^[1]
• A history of thrombotic APS: LDA plus therapeutic-dose heparin throughout pregnancy. ^[1]
• Switch from warfarin to LMWH or unfractionated heparin as soon as pregnancy is confirmed, ideally before the sixth week, because warfarin is teratogenic. ^[1]
• Where obstetric APS is treated with prophylactic heparin in pregnancy, the same heparin dose should be continued for six weeks after delivery to reduce maternal thrombosis risk. ^[1]
• LDA is preferably started before conception.

• In unprovoked venous thrombosis, long-term anticoagulation reduced recurrences compared with stopping after three to six months, based on two small studies (one randomised, one cohort), although evidence is indirect and high-quality trials are lacking. ^[2]
• Women with recurrent first-trimester losses treated with LDA plus heparin had higher live-birth rates than with LDA alone (pooled relative risk 1.23, 95% confidence interval 1.12 to 1.35), and miscarriages were reduced. ^[2]
• Women with a history of fetal loss had similar benefit with combined LDA and heparin versus LDA alone (pooled relative risk for live births 1.19). ^[2]

• Prevent by minimising interruptions in anticoagulation (especially around surgery) and by early treatment of infections. ^[1]
• First-line treatment combines heparin, glucocorticoids and plasma exchange or IVIG; any trigger (infection, gangrene, malignancy) must be treated. ^[1]
• Refractory cases may be treated with B-cell depletion (rituximab) or complement inhibition (eculizumab). ^[1]

• Recurrent thrombosis, the defining long-term risk, most often in the same vascular bed as the first event. ^[1]
• Catastrophic APS with multi-organ microvascular thrombosis. ^{[1] [4]}
• Bleeding from anticoagulation, especially with high INR targets, older age and drug interactions.
• Pregnancy complications: severe pre-eclampsia, fetal growth restriction, fetal death.
• Non-thrombotic: thrombocytopenia, autoimmune haemolytic anaemia, livedoid vasculopathy and APS nephropathy. ^[4]

Prognosis is generally good if thrombosis is treated promptly and anticoagulation is maintained, but APS remains life-long and unpredictable.

• About 91% 10-year survival in large cohorts. ^[4]
• Catastrophic APS carries about 50% mortality despite treatment. ^[4]
• Arterial events, especially stroke, have the greatest impact on long-term disability. ^[1]
• Obstetric outcomes are good with combination aspirin and heparin in pregnancy. ^[2]

• Do not screen the general population; test when clinically appropriate: unprovoked thrombosis at a young age or unusual sites, recurrent miscarriage or fetal death, severe early-onset pre-eclampsia, systemic autoimmune disease (especially SLE), thrombocytopenia plus livedo. ^{[5] [6]}
• Test aCL and anti-beta-2-glycoprotein I by standardised ELISA and LA by clotting assays. ^[6]
• Confirm persistence at 12 weeks. ^{[1] [10]}
• Use thromboprophylaxis in high-risk situations (surgery, prolonged immobility, postpartum) for aPL carriers. ^[1]
• Manage traditional risk factors aggressively: stop smoking, treat hypertension, dyslipidaemia and diabetes. ^[1]

Covered above. The two rules are: switch warfarin to heparin before the sixth week, and continue anticoagulation postpartum.

APS overlaps most often with SLE, and aPL are commonly present. Test patients with SLE at least once, because high-risk profiles merit LDA prophylaxis and change management after thrombosis or pregnancy complications. ^[1]

APS is relatively uncommon in children. A first thrombosis or stroke at a young age needs full thrombophilia and APS workup, and a congenital thrombophilia workup where appropriate.

After a stroke in an older patient, aPL can be a confounder because low-titre positivity is common with age. APS should be diagnosed only when antibodies persist at medium-high titre and fit the clinical picture; treatment should still be driven by the vascular risk profile. ^[3]

In secondary APS, control of the underlying disease matters; hydroxychloroquine is often continued because of its antithrombotic and SLE benefits.

• APL testing may be limited. Send at least one screen (LA plus aCL/anti-beta-2-glycoprotein I) where possible, and repeat at 12 weeks if budgets allow; if only one sample is possible, note uncertainty and treat clinically.
• Low-dose aspirin and warfarin are inexpensive and widely available, so primary and secondary prophylaxis are feasible even where DOACs and LMWH are not.
• INR monitoring with warfarin is the practical barrier: plan frequent early checks, then stable spacing; self-testing programmes where available.
• LMWH is costly for long periods but is needed in pregnancy and in bridging; unfractionated heparin can be used where it is the only option.
• Heparin prophylaxis before surgery and early infection treatment are low-cost measures to prevent catastrophic APS.

MCTD is rare and was first described by Sharp in 1972 in 25 patients with lupus, scleroderma and inflammatory muscle disease who shared anti-U1 RNP. Whether MCTD is a separate disease or an early stage of a definite connective tissue disease is still debated; a minority evolve to SLE, systemic sclerosis or an inflammatory myopathy over time. ^[7]

Anti-U1 RNP is the immunological hallmark: antibodies against the 70-kDa U1-RNP and related spliceosomal proteins. High titre is expected. It binds ribonucleoprotein and is part of the extractable nuclear antigen panel. A positive ANA with a speckled pattern often points towards U1 RNP.

• Raynaud phenomenon, often severe and sometimes accompanied by digital ischaemic ulcers.
• Puffy fingers and hand oedema, with or without sclerodactyly later.
• Arthritis and tenosynovitis, often resembling rheumatoid arthritis but usually non-erosive.
• Inflammatory myopathy with muscle weakness and raised creatine kinase.
• Interstitial lung disease and oesophageal dysmotility.
• Pleuritis and pericarditis.
• Leukopenia and thrombocytopenia.
• Trigger (trigeminal) neuralgia and aseptic meningitis in some patients.
• Pulmonary arterial hypertension, which is the serious late complication to monitor for.

There is no universally agreed international diagnostic criteria. The clinical rule most clinicians accept is:

• High-titre positive anti-U1 RNP; and
• Raynaud phenomenon, puffy fingers, or hand oedema; and
• At least two of: synovitis, myositis, leukopenia, oesophageal dysmotility, pleuritis, pericarditis or interstitial lung disease. ^[7]

In 2019 a Japanese consensus panel proposed revised criteria with four feature categories (common, immunological, organ involvement and overlapping manifestations), with reported sensitivity of 90.6% and specificity of 98.4%; these have not been formally adopted internationally. ^[7]

Management is by organs and disease activity rather than by a single protocol:

• Hydroxychloroquine and low-dose corticosteroids for inflammatory arthritis and skin features.
• Immunosuppression for active myositis and interstitial lung disease, under rheumatology and respirology.
• Screening for and treatment of pulmonary arterial hypertension.
• General connective tissue measures (smoking cessation, cold protection for Raynaud, gastro-oesophageal reflux treatment).
• APL, which may coexist in a minority of these patients, should be tested when thrombosis occurs and treated as described above.

MCTD is not APS, but the two overlap conditions can coexist because both are autoimmune. A patient with MCTD who develops venous or arterial thrombosis, livedo or pregnancy loss should be tested for persistent aPL and managed as APS on top of their MCTD regimen.

UCTD is common in clinical practice and is often the "pre-diagnosis" phase of a named disease. Patients may have arthralgia, Raynaud phenomenon, skin rash, sicca symptoms or haematological abnormalities, with positive antinuclear antibodies and sometimes specific autoantibodies, but not enough criteria for SLE, systemic sclerosis or another disease. ^[9]

The widely used preliminary criteria, still not formally validated, require: ^{[8] [9]}

• Signs and symptoms suggestive of a connective tissue disease but not fulfilling criteria for a defined disease;
• Positive antinuclear antibodies on two separate measurements; and
• Disease duration of at least three years.

The three-year duration rule is what separates "stable UCTD" (prognostically milder) from "evolving UCTD" that may become lupus or scleroderma within the first years. ^[9]

From a long-term single-centre cohort of stable UCTD (141 patients, median 8 years' follow-up): ^[9]

• Presenting symptoms: arthralgia/arthritis in about 52%, Raynaud phenomenon in about 50%, skin rash in about 18%, and sicca in about 11%. ^[9]
• All patients were ANA positive; anti-Ro in about 27%, aPL (lupus anticoagulant and/or anticardiolipin and/or anti-beta-2-glycoprotein I) in about 25%, anti-U1 RNP in about 5.5%, anti-dsDNA in about 5%, hypocomplementaemia in 45%. ^[9]
• About 40% of UCTD at onset evolves into a defined connective tissue disease, but in this cohort of stable (more than 3 years) disease, 11.3% evolved over a median of 11 years (range roughly 6 to 25 years), becoming SLE in 7%, Sjögren disease 1.4%, systemic sclerosis 0.7%, inflammatory myopathy 0.7%, or overlap syndrome 1.4%. ^[9]
• Organ damage (on the SLE damage index) was seen in 27.3% at last visit, with neoplasia the most common event; mean age at first damage was 44 years after about 7.8 years of disease. ^[9]
• Common comorbidities were autoimmune thyroiditis in 29% and fibromyalgia in 26%. ^[9]
• At the last visit, about 68% were on antimalarials, 10% on glucocorticoids and 6% on immunosuppressive therapy. ^[9]

There are no approved drugs specifically for UCTD, so treatment is expectant and based on symptoms:

• Hydroxychloroquine and NSAIDs for arthralgia, rash, Raynaud and minor inflammatory features; limited data but antimalarial use is widespread.
• Low-dose glucocorticoids for flares, used sparingly.
• Immunosuppressive agents only for organ-threatening features (haematological, renal, pulmonary), used as in the corresponding CTD.
• Annual or twice-yearly review, because evolution can be late, plus screening for comorbid organ-specific autoimmune disease and standard cancer screening.
• Organ damage prevention: minimise chronic glucocorticoid exposure, control blood pressure and lipids, bone health.
• APL present in about a quarter of UCTD patients in one cohort means any thrombosis, livedo or pregnancy loss should prompt APS-style management. ^[9]
• Pregnancy should be planned; the pregnancy outcome literature is limited but resembles that of mild connective tissue disease. ^[9]

The main clinical challenge is deciding whether a patient has "early SLE" rather than UCTD. The distinction matters for prognosis and treatment. Anti-dsDNA and anti-Sm antibodies, hypocomplementaemia, alopecia, oral ulcers and cytopenias favour lupus; in the absence of those, UCTD is the working diagnosis, with regular review. ^[9]

• APS is defined by persistent aPL plus thrombosis or pregnancy morbidity; it can be primary or secondary to SLE. ^[1]
• The three antibodies are lupus anticoagulant, anticardiolipin and anti-beta-2-glycoprotein I; positivity must be confirmed on two occasions at least 12 weeks apart. ^{[1] [10]}
• Risk stratification uses the aPL profile: LA, double/triple positivity and persistently high titres define high risk; an isolated low-to-moderate titre antibody defines low risk. ^[1]
• Medium-high titre anticardiolipin means greater than 40 phospholipid units (GPL/MPL) or greater than the 99th percentile; anti-beta-2-glycoprotein I greater than the 99th percentile. ^[1]
• Primary prevention: low-dose aspirin for high-risk aPL carriers, for SLE patients with a high-risk profile, and for women with obstetric APS (after risk-benefit). ^[1]
• Venous thrombosis: warfarin target INR 2-3, long term if unprovoked; INR above 3 is not superior to 2-3 for venous thrombosis. ^{[1] [2]}
• Arterial thrombosis: warfarin over aspirin; target INR 2-3 or 3-4 judged case by case, or 2-3 plus low-dose aspirin. ^[1]
• Rivaroxaban (and DOACs) are not suitable for patients with triple aPL positivity, particularly with arterial events; LMWH is the fallback for pregnancy, bridging and resistant disease. ^{[1] [2]}
• Obstetric APS: low-dose aspirin plus prophylactic heparin in pregnancy; therapeutic heparin if there was prior thrombosis; a switch from warfarin before 6 weeks' gestation; heparin continued for 6 weeks postpartum. ^[1]
• Proven bedrock: venous thrombosis LDA+heparin in pregnancy raises live births (pooled relative risk 1.23 for first-trimester losses; 1.19 for fetal loss). ^[2]
• Catastrophic APS is about 1% of cases with about 50% mortality; prevent by avoiding interruptions in anticoagulation and treating infection early. ^[4]
• Ten-year survival in APS is about 91%. ^[4]
• The 2023 ACR/EULAR criteria (specificity 99%, sensitivity 84%) are more specific than the 2006 Sydney criteria, but Sydney remains widely used; neither replaces clinical judgement. ^[3]
• MCTD is an anti-U1 RNP-positive overlap syndrome of lupus, scleroderma and myositis; anti-U1 RNP is required and high-titre. ^[7]
• UCTD is incomplete autoimmunity, often ANA positive; most are stable, but up to 40% can evolve into a named disease, so review long term. ^{[8] [9]}
• About a quarter of stable UCTD patients carry aPL; thrombosis or pregnancy loss in these patients should be treated as APS. ^[9]

• Systemic lupus erythematosus
• Sjogren disease
• Systemic sclerosis
• Inflammatory myopathies
• Rheumatoid arthritis
• Thrombophilia and venous thromboembolism
• Pregnancy and anticoagulation
• Livedo and antiphospholipid syndrome